Exogenous Testosterone Use Increases the Risk of Central Serous Chorioretinopathy
Abstract
OBJECTIVE: To evaluate the association between exogenous testosterone (ExoT) use and central serous chorioretinopathy (CSCR).
DESIGN: Retrospective observational cohort study using large-scale electronic health record data.
SUBJECTS/PARTICIPANTS: Patients receiving ExoT therapy, identified from the MarketScan and STARR databases.
METHODS: Data were accessed from two sources: Merative MarketScan Commercial Database and Stanford's Clinical Data Warehouse (STARR), which aggregates deidentified patient records from Stanford Health Care. Patients on testosterone therapy were included and categorized by CSCR status. Demographic factors such as sex (administrative field), race, and ethnicity were assessed. Laboratory values (testosterone, hematocrit, red blood cell counts count, cortisol) were compared in STARR, with limited availability in MarketScan. Logistic regression analyses were performed in MarketScan, adjusting for age and sex. A sensitivity analysis restricted to patients exposed to ExoT prior to CSCR diagnosis was also performed.
MAIN OUTCOME MEASURES: The primary outcomes were CSCR prevalence and adjusted odds ratios for CSCR risk in patients on ExoT. Secondary outcomes included differences in laboratory values and treatment requirements (photodynamic therapy and intravitreal injections).
RESULTS: In STARR, individuals with CSCR on ExoT had significantly higher mean testosterone levels (P = .001), hematocrit (P = .022), and red blood cell counts (P = .005) compared to…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.